DV
Dividend Vision

CLLS — Cellectis SA

Cellectis SA (CLLS)

Total return is -92.2% over the past 11.4 years, 447.0 points behind SPY at 354.8%. Its deepest 1-year drawdown was 51.4%.

CLLS is an equity stock that tracks Cellectis SA, a biotechnology company focused on gene-editing and cellular immunotherapy. The holding does not currently distribute dividends and carries no stated expense ratio or asset under management data. This security appeals primarily to investors seeking exposure to the biotech sector rather than dividend income, as it operates as a single-stock position without a traditional ETF fund structure or yield profile.

CLLS key facts

Asset type
Stock
Asset class
Equity
Inception date
03/25/2015
Last close
$3.05
Market cap
$264,836,176
Average volume
15200.0
Beta
2.765
Payout ratio
0.0
Forward P/E
0.0
EPS
$-0.67